Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-4652-3p mimic
- Development stage
- Preclinical
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
miR-4652-3p mimic is a synthetic double-stranded RNA oligonucleotide designed to simulate the biological activity of the endogenous microRNA miR-4652-3p. In the context of non-small cell lung cancer (NSCLC), miR-4652-3p acts as a tumor suppressor by inhibiting glutamine metabolism. It achieves this by directly targeting and downregulating the expression of the MYC proto-oncogene and the neutral amino acid transporter SLC1A5 (also known as ASCT2). By suppressing the MYC/SLC1A5 axis, the mimic reduces the inflammatory microenvironment-induced metabolic reprogramming that supports cancer cell proliferation and survival.
- Other names
- microRNA-4652-3p mimicmicroRNA4652-3p mimicmicroRNA 4652-3p mimichsa-miR-4652-3p mimichsa-miR4652-3p mimichsa-miR 4652-3p mimic
02
Targets
SLC1A5 (Alanine/serine/cysteine transporter 2)MYC (MYC proto-oncogene protein)
Beyond the preview
Go deeper on miR-4652-3p mimic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-4652-3p mimic.